References
- Tumgor G. Cirrhosis and hepatopulmonary syndrome. World J Gastroenterol 2014;20:2586–94.
- Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology 2014;59:1627–37.
- Luo B, Tang L, Wang Z, Zhang J, Ling Y, Feng W, et al. Cholangiocyte endothelin-1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome. Gastroenterology 2005;129:682–95.
- Liu L, Liu N, Zhao Z, Liu J, Feng Y, Jiang H, et al. TNF-alpha neutralization improves experimental hepatopulmonary syndrome in rats. Liver Int 2012;32:1018–26.
- Karabulut A, Iltumur K, Yalcin K, Toprak N. Hepatopulmonary syndrome and right ventricular diastolic functions: an echocardiographic examination. Echocardiography 2006;23:271–8.
- Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126–38.
- Tripathi D, Therapondos G, Ferguson JW, Newby DE, Webb DJ, Hayes PC. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 2006;55:1290–5.
- Khoshbaten M, Rostami Nejad M, Ansarin K, Fatemi R, Dulaimi DA, et al. The association between clinical symptoms, laboratory findings and serum endothelin 1 concentrations in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterol Hepatol Bed Bench 2012;5:S13–19.
- Li SR, Shen N, Yi HM, Gan XL, Hei ZQ. Changes of systemic and pulmonary hemodynamics and plasma levels of inducible nitric oxide synthase and endothelin-1 in patients with hepatopulmonary syndrome. Nan Fang Yi Ke Da Xue Xue Bao 2009;29:2030–2.
- Feng G, Rong H. The role of hemodynamic and vasoactive substances on hepatopulmonary syndrome. Eur Rev Med Pharmacol Sci 2014;18:380–6.
- Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Nat Acad Sci USA 2011;98:12814–19.
- Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 2006;40:295–302.
- Dal-Ros S, Oswald-Mammosser M, Pestrikova T, Schott C, Boehm N, et al. Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats. Gastroenterology 2010;138:1574–84.
- Kondrikov D, Elms S, Fulton D, Su Y. eNOS-beta-actin interaction contributes to increased peroxynitrite formation during hyperoxia in pulmonary artery endothelial cells and mouse lungs. J Biol Chem 2010;285:35479–87.
- Ferré N, Camps J, Prats E, Vilella E, Paul A, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002;48:261–8.
- Annie-Jeyachristy S, Geetha A, Surendran R, Sundaram A, Lavanya K, Kumar SJ, et al. Level of nitrated proteins in the plasma, platelets and liver of patients with liver cirrhosis. Redox Rep 2009;14:259–66.
- Sugiura H, Ichinose M. Nitrative stress in inflammatory lung diseases. Nitric Oxide 2011;25:138–44.
- Zhao YY, Malik AB. A. Novel Insight into the Mechanism of Pulmonary Hypertension Involving Caveolin-1 Deficiency and eNOS Activation. Trends Cardiovasc Med 2009;19:238–42.
- Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension. response to bosentan therapy. Am J Resp Crit Care Med 2005;172:352–7.
- Cremona G, Higenbottam TW, Mayoral V, Alexander G, Demoncheaux E, Borland C, et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 1995;8:1883–5.
- Basili S, Raparelli V, Riggio O, Merli M, Carnevale R, Angelico F, et al. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. Liver Int 2011;31:1533–40.